Key releases are ad hoc announcements pursuant to SIX Swiss Exchange Art. 53 LR Year None202620252024 March 21, 2025 Annual Report and the invitation to its first Annual General Meeting March 6, 2025 Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency¹, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond February 14, 2025 Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis December 13, 2024 Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis October 24, 2024 Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance August 13, 2024 Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis August 5, 2024 Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology July 30, 2024 Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe July 25, 2024 Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024 April 24, 2024 Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Next page next › Last page last » Displaying 11 - 20 of 21